Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
<p>BACKGROUND: In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational studies, larger increases in many different AEs have been reported than in blinded trials.</p><p> METHODS: In the Lipid-Lowering A...
Main Authors: | Gupta, A, Thompson, D, Whitehouse, A, Collier, T, Dahlof, B, Poulter, N, Collins, R, Sever, P, ASCOT Investigators |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2017
|
Similar Items
-
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
by: Sever, P, et al.
Published: (2005) -
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
by: Sever, P, et al.
Published: (2004) -
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
by: Sever, P, et al.
Published: (2003) -
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.
by: Sever, P, et al.
Published: (2001) -
The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb (ASCOT-BPLA): effects in patients with type 2 diabetes
by: Ostergren, J, et al.
Published: (2006)